Humira
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Humira in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Humira.
2
Global Revenue Ranking
Recent articles on PMLiVE featuring Humira
Making launch more effective, precise, cost-effective and agile demands new thinking and new technologies
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade
The drug is approved for inflammatory conditions such as Crohn’s disease and plaque psoriasis
Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease
The drug is available in Scotland on the NHS to treat the chronic inflammatory condition
How the UK can harness the potential of mRNA technology to play a global leading role and be a driving force of the bio-industrial revolution
Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease
Some companies should be careful what they wish for
The move could reduce out-of-pocket costs for Medicare beneficiaries by up to $390 per dose
With strong growth in specialty care, vaccines and consumer health seeing sales rise by 10% in the third quarter, Sanofi now expects earnings to grow by 14% in 2021
The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling
Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology